Third Wave Drops HCV Suit Against Chiron, Bayer

Law360, New York (February 23, 2006, 12:00 AM EST) -- Resolving all but one of the company’s patent-related disputes, molecular diagnostics company Third Wave Technologies Inc. has dismissed without prejudice its suit against rivals Chiron Corp. and Bayer Corp. over technology related to the hepatitis C virus, or HCV.

Third Wave’s dispute with Stratagene Corp. over patent infringement is ongoing.

No licenses were granted or taken under the agreement, whose terms were not disclosed, and no payment was made to any of the companies, according to a Third Wave press release.

Third Wave initiated the litigation...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.